Skip to content

In the BioHarmony Drug Report Database

Cannabidiol

Epidiolex, Epidyolex (cannabidiol) is a small molecule pharmaceutical. Cannabidiol was first approved as Epidiolex on 2018-09-28. It is used to treat anxiety, lennox gastaut syndrome, myoclonic epilepsies, and pain in the USA. It has been approved in Europe to treat lennox gastaut syndrome and myoclonic epilepsies. It is known to target N-arachidonyl glycine receptor, transient receptor potential cation channel subfamily V member 2, G-protein coupled receptor 55, transient receptor potential cation channel subfamily M member 8, transient receptor potential cation channel subfamily A member 1, transient receptor potential cation channel subfamily V member 3, and cannabinoid receptor 1. Epidiolex's patents are valid until 2035-10-14 (FDA).
Trade Name Epidyolex
Common Name Cannabidiol
Indication anxiety, lennox gastaut syndrome, myoclonic epilepsies, pain
Drug Class Cannabinol derivatives
Cannabidiol
Get full access now